SYMPHONY-1
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- NCT04224493 ↗
- Active, not recruiting
- Epizyme, Inc.
- Standard
We haven't built an HCP commentary report on SYMPHONY-1 (tazemetostat in relapsed/refractory follicular lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SYMPHONY-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 6 | |
| X threads | 4 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma
- Interventions
- Tazemetostat; Tazemetostat; Placebo oral tablet; Lenalidomide; Rituximab
- Arms
- Tazemetostat + R2 arm · Experimental
- Placebo + R2 Arm · Placebo comparator
- Enrollment
- 599
- Primary outcomes
- Phase 1b: Recommended Phase 3 Dose (RP3D) of tazemetostat in combination with rituximab and lenalidomide (R2)
- Phase 3: Progression-Free Survival (PFS) in the Intent-to-treat wild-type (ITT-WT) populations
- Phase 3: PFS in the Intent-to-treat mutant-type (ITT-MT) population
- Phase 3: PFS in the R/R FL population regardless of mutation status by Investigator assessment
- Phase 3: Progression-Free Survival (PFS) in the all comer (ITT-All) populations.
- Sponsor
- Epizyme, Inc.
- Start
- Jun 11, 2020
- Primary completion
- Feb 13, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04224493 · updated Oct 5, 2026
Publications
linked from the registry- Cao J, Chen G, Qiu L, Zhang L, Jiang M, Cheng Y, Zhang Q, Liu L, Li P, Shuang Y, Wang H, Xue H, Wu H, Zheng M, Zhou K, Li Z, Jing H, Yang W, Zhu Z, Li W, Wangwu J, Huang H, Jia Q, Chen D, Fan S, Shi MM, Su W. Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study. EClinicalMedicine. 2025 Aug 18;87:103399. doi: 10.1016/j.eclinm.2025.103399. eCollection 2025 Sep. PubMed 40896460